Polyhydroquinoline derivatives for diabetic management: synthesis, in vitro and in silico approaches

Future Med Chem. 2023 Dec;15(23):2195-2208. doi: 10.4155/fmc-2023-0232. Epub 2023 Nov 24.

Abstract

Background: Medication used to treat Type 2 diabetes by decreasing the absorption of carbohydrates in the intestine consists of α-glucosidase inhibitors. Polyhydroquinoline derivatives have attracted interest as excellent antidiabetic agents. Methods: Polyhydroquinoline derivatives (1-17) were synthesized and tested for in vitro α-glucosidase inhibitory activity. Results: All the synthesized compounds exhibited excellent to good inhibitory activity, having IC50 values from 1.23 ± 0.03 to 73.85 ± 0.61 μM, compared with the standard drug, acarbose. The binding mechanism of these derivatives with α-glucosidase was deduced by docking studies and indicated that a slight variation in the orientation of compounds, affects their binding capability. Conclusion: In order to find new antidiabetic drugs, this study has discovered prospective lead candidates.

Keywords: NMR spectroscopy; molecular docking; polyhydroquinoline; structure–activity relationship; α-glucosidase.

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Molecular Docking Simulation
  • Molecular Structure
  • Prospective Studies
  • Structure-Activity Relationship
  • alpha-Glucosidases* / metabolism

Substances

  • alpha-Glucosidases
  • Hypoglycemic Agents